Cover Image
市場調查報告書

Panacea Biotec Limited :產品平台分析

Panacea Biotec Limited - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 251515
出版日期 內容資訊 英文 55 Pages
訂單完成後即時交付
價格
Back to Top
Panacea Biotec Limited :產品平台分析 Panacea Biotec Limited - Product Pipeline Review - 2016
出版日期: 2016年07月30日 內容資訊: 英文 55 Pages
簡介

Panacea Biotec Limited是研究型健康管理企業,正在致力於醫藥品、生化醫藥品、疫苗,以及天然產品之研究開發、製造、商品化。該公司同時也提供腫瘤、腎臟病、器官移植、疼痛管理、糖尿病管理等領域之製劑處方。

本報告提供Panacea Biotec Limited 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Panacea Biotec Limited的基本資料

  • Panacea Biotec Limited概要
  • 主要資訊
  • 企業資料

Panacea Biotec Limited:R&D概要

  • 主要的治療範圍

Panacea Biotec Limited:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式

Panacea Biotec Limited:開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Panacea Biotec Limited:藥物簡介

  • diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae serotype B + polio (hexavalent) vaccine
  • diphtheria + tetanus + pertussis (whole cell) + haemophilus influenzae serotype B + polio (pentavalent) vaccine
  • Nucovac
  • polio sabin vaccine
  • PBL-1427
  • bevacizumab biosimilar
  • cetuximab biosimilar
  • darbepoetin alfa
  • etanercept biosimilar
  • hepatitis-B vaccine
  • Japanese encephalitis vaccine
  • omalizumab biosimilar
  • Peptide for Alopecia
  • rituximab biosimilar
  • trastuzumab biosimilar
  • dengue (tetravalent) vaccine
  • influenza vaccine
  • meningococcal polysaccharide vaccine
  • pertussis (acellular) vaccine
  • pneumococcal vaccine
  • Recombinant Protein for Renal Anemia
  • respiratory syncytial virus vaccine
  • Synthetic Peptides to Agonize GLP-1 for Type 2 Diabetes
  • yellow fever vaccine

Panacea Biotec Limited:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Panacea Biotec Limited:最近的開發平台趨勢

Panacea Biotec Limited:暫停中的計劃

Panacea Biotec Limited:企業發表

Panacea Biotec Limited:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08107CDB

Summary

Global Markets Direct's, 'Panacea Biotec Limited - Product Pipeline Review - 2016', provides an overview of the Panacea Biotec Limited's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Panacea Biotec Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Panacea Biotec Limited
  • The report provides overview of Panacea Biotec Limited including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Panacea Biotec Limited's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Panacea Biotec Limited's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Panacea Biotec Limited's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Panacea Biotec Limited
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Panacea Biotec Limited's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Panacea Biotec Limited Snapshot
    • Panacea Biotec Limited Overview
    • Key Information
    • Key Facts
  • Panacea Biotec Limited - Research and Development Overview
    • Key Therapeutic Areas
  • Panacea Biotec Limited - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
  • Panacea Biotec Limited - Pipeline Products Glance
    • Panacea Biotec Limited - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Panacea Biotec Limited - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Panacea Biotec Limited - Early Stage Pipeline Products
      • Preclinical oducts/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
    • Panacea Biotec Limited - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • Panacea Biotec Limited - Drug Profiles
    • (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + polio + tetanus) (hexavalent) vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • polio [strain Sabin] vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Nucovac
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bevacizumab biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cetuximab biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • darbepoetin alfa
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • etanercept biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • hepatitis B vaccine 2
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • omalizumab biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rituximab biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptide for Alopecia
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • trastuzumab biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dengue (tetravalent) vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • influenza vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Japanese encephalitis vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • meningococcal vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pertussis (acellular) vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pneumococcal vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • respiratory syncytial virus vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptides to Agonize GLP-1 for Type 2 Diabetes
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • yellow fever vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein for Autoimmune Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein for Renal Anemia
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Panacea Biotec Limited - Pipeline Analysis
    • Panacea Biotec Limited - Pipeline Products by Target
    • Panacea Biotec Limited - Pipeline Products by Route of Administration
    • Panacea Biotec Limited - Pipeline Products by Molecule Type
    • Panacea Biotec Limited - Pipeline Products by Mechanism of Action
  • Panacea Biotec Limited - Recent Pipeline Updates
  • Panacea Biotec Limited - Dormant Projects
  • Panacea Biotec Limited - Company Statement
  • Panacea Biotec Limited - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Panacea Biotec Limited, Key Information
  • Panacea Biotec Limited, Key Facts
  • Panacea Biotec Limited - Pipeline by Indication, 2016
  • Panacea Biotec Limited - Pipeline by Stage of Development, 2016
  • Panacea Biotec Limited - Monotherapy Products in Pipeline, 2016
  • Panacea Biotec Limited - Combination Treatment Modalities in Pipeline, 2016
  • Panacea Biotec Limited - Phase III, 2016
  • Panacea Biotec Limited - Phase II, 2016
  • Panacea Biotec Limited - Phase I, 2016
  • Panacea Biotec Limited - Preclinical, 2016
  • Panacea Biotec Limited - Discovery, 2016
  • Panacea Biotec Limited - Unknown, 2016
  • Panacea Biotec Limited - Pipeline by Target, 2016
  • Panacea Biotec Limited - Pipeline by Route of Administration, 2016
  • Panacea Biotec Limited - Pipeline by Molecule Type, 2016
  • Panacea Biotec Limited - Pipeline Products by Mechanism of Action, 2016
  • Panacea Biotec Limited - Recent Pipeline Updates, 2016
  • Panacea Biotec Limited - Dormant Developmental Projects,2016
  • Panacea Biotec Limited, Other Locations
  • Panacea Biotec Limited, Subsidiaries

List of Figures

  • Panacea Biotec Limited - Pipeline by Top 10 Indication, 2016
  • Panacea Biotec Limited - Pipeline by Stage of Development, 2016
  • Panacea Biotec Limited - Monotherapy Products in Pipeline, 2016
  • Panacea Biotec Limited - Pipeline by Top 10 Target, 2016
  • Panacea Biotec Limited - Pipeline by Route of Administration, 2016
  • Panacea Biotec Limited - Pipeline by Top 10 Molecule Type, 2016
  • Panacea Biotec Limited - Pipeline Products by Mechanism of Action, 2016
Back to Top